Crossmark

ADAMDEC1-driven CCL2-CCR2-PD-1 axis in esophageal squamous cell carcinoma: a dual threat of O-GlcNAcylation and m6A methylation in neoadjuvant therapy resistance and immune evasion

Crossref DOI link: https://doi.org/10.1007/s13402-026-01204-7

Published Online: 2026-04-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Cheng, Jiwei

Ma, Haibo

Qian, Xin

Xing, Wenqun
Funding

Funding for this research was provided by:

a key project jointly built by the provincial and ministerial authorities of the Health Commission of Henan Province (SBGJ202002019)
License Information

Text and Data Mining valid from 2026-04-07

Version of Record valid from 2026-04-07
More Information

Article History

Received: 8 January 2026

Accepted: 27 March 2026

First Online: 7 April 2026

Declarations

:

: The study was approved by the Institutional Ethics Committee of the Affiliated Cancer Hospital of Zhengzhou University. All experimental procedures were conducted in compliance with institutional animal care protocols approved by the Animal Experimentation Ethics Committee at the Affiliated Cancer Hospital of Zhengzhou University.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below